These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1430 related articles for article (PubMed ID: 27207799)

  • 1. Toxicities of chimeric antigen receptor T cells: recognition and management.
    Brudno JN; Kochenderfer JN
    Blood; 2016 Jun; 127(26):3321-30. PubMed ID: 27207799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
    Shank BR; Do B; Sevin A; Chen SE; Neelapu SS; Horowitz SB
    Pharmacotherapy; 2017 Mar; 37(3):334-345. PubMed ID: 28079265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
    Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
    J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
    Banerjee R; Fakhri B; Shah N
    Leuk Lymphoma; 2021 Nov; 62(11):2600-2611. PubMed ID: 34151714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
    Bailey SR; Vatsa S; Larson RC; Bouffard AA; Scarfò I; Kann MC; Berger TR; Leick MB; Wehrli M; Schmidts A; Silva H; Lindell KA; Demato A; Gallagher KME; Frigault MJ; Maus MV
    Blood Cancer Discov; 2022 Mar; 3(2):136-153. PubMed ID: 35015685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicities associated with adoptive cellular therapies.
    Hansen DK; Dam M; Faramand RG
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current understanding and management of CAR T cell-associated toxicities.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
    Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team.
    Martino M; Macheda S; Aguglia U; Arcudi L; Pucci G; Martino B; Altomonte M; Rossetti AM; Cusumano G; Russo L; Imbalzano L; Stelitano C; Alati C; Germano' J; Labate D; Amalfi V; Florenzano MT; Morabito A; Borzumati V; Dattola V; Gattuso C; Moschella A; Quattrone D; Curmaci F; Franzutti C; Scappatura G; Rao CM; Loddo V; Pontari A; Pellicano' M; Surace R; Sanguedolce C; Naso V; Ferreri A; Irrera G; Console G; Moscato T; Loteta B; Canale FA; Trimarchi A; Monteleone R; Al Sayyad S; Cirrone F; Bruno B
    Expert Opin Biol Ther; 2022 Mar; 22(3):407-421. PubMed ID: 34463175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.
    Frey N; Porter D
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):e123-e127. PubMed ID: 30586620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
    Park JH; Geyer MB; Brentjens RJ
    Blood; 2016 Jun; 127(26):3312-20. PubMed ID: 27207800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
    Yoo JW
    Blood Res; 2023 Apr; 58(S1):S20-S28. PubMed ID: 36891576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T Cell Therapies From the Transfusion Medicine Perspective.
    Fesnak A; Lin C; Siegel DL; Maus MV
    Transfus Med Rev; 2016 Jul; 30(3):139-45. PubMed ID: 27067907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.